MapLight Therapeutics Inc

MapLight insiders sell shares to cover RSU taxes, while executives buy back—investors see modest supply pressure, but potential upside from Q3 2026 clinical data.

MapLight insider sales reveal steady ownership and disciplined tax‑related selling—no panic signs, but watch the 180‑day lock‑up for a supply shock.

MapLight insider sells 33,728 shares in Jan 2026—tax‑driven exits, liquidity impact, and what it means for investors.